title: Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.
abstract: Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5-6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2-4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.
authors.forename: Ekaterina V
authors.initials: EV
authors.lastname: Kurbatova
authors.forename: Tracy
authors.initials: T
authors.lastname: Dalton
authors.forename: Julia
authors.initials: J
authors.lastname: Ershova
authors.forename: Thelma
authors.initials: T
authors.lastname: Tupasi
authors.forename: Janice Campos
authors.initials: JC
authors.lastname: Caoili
authors.forename: Martie
authors.initials: M
authors.lastname: Van Der Walt
authors.forename: Charlotte
authors.initials: C
authors.lastname: Kvasnovsky
authors.forename: Martin
authors.initials: M
authors.lastname: Yagui
authors.forename: Jaime
authors.initials: J
authors.lastname: Bayona
authors.forename: Carmen
authors.initials: C
authors.lastname: Contreras
authors.forename: Vaira
authors.initials: V
authors.lastname: Leimane
authors.forename: Laura E
authors.initials: LE
authors.lastname: Via
authors.forename: HeeJin
authors.initials: H
authors.lastname: Kim
authors.forename: Somsak
authors.initials: S
authors.lastname: Akksilp
authors.forename: Boris Y
authors.initials: BY
authors.lastname: Kazennyy
authors.forename: Grigory V
authors.initials: GV
authors.lastname: Volchenkov
authors.forename: Ruwen
authors.initials: R
authors.lastname: Jou
authors.forename: Kai
authors.initials: K
authors.lastname: Kliiman
authors.forename: Olga V
authors.initials: OV
authors.lastname: Demikhova
authors.forename: J Peter
authors.initials: JP
authors.lastname: Cegielski
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*
chemical_list: D000995:Antitubercular Agents
keywords: antimicrobial resistance; bacteria; multidrug-resistant tuberculosis; second-line drug resistance; tuberculosis; tuberculosis and other mycobacterial infections